Your browser doesn't support javascript.
loading
Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice
Journal of the Egyptian Society of Parasitology. 1999; 29 (3): 791-803
em Inglês | IMEMR | ID: emr-51187
ABSTRACT
The standard regimen of treatment for toxoplasmosis is pyrimethamine with sulfadiazine. However, it is not suitable in some conditions and non-tolerable in AIDs patients. Deferoxamine [DFO], an iron chelator, is well tolerated clinically in transfusion induced-iron overload. The present study had shown that DFO is a promising drug against acute toxoplasmosis in mice. Three doses of 200, 300 and 400 mg/kg DFO were used either alone or in combination with pyrimethamine. Singly, it was effective in a dose-related response with the resultant of 70% protection of infected mice. When DFO was combined with a low minimally effective dose of pyrimethamine, a 100% protection was recorded with the prolongation in duration of survival of mice. Different possible mechanisms of action of DFO against Toxoplasma gondii were discussed
Assuntos
Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Pirimetamina / Doença Aguda / Desferroxamina / Quimioterapia Combinada / Camundongos Limite: Animais Idioma: Inglês Revista: J. Egypt. Soc. Parasitol. Ano de publicação: 1999

Similares

MEDLINE

...
LILACS

LIS

Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Pirimetamina / Doença Aguda / Desferroxamina / Quimioterapia Combinada / Camundongos Limite: Animais Idioma: Inglês Revista: J. Egypt. Soc. Parasitol. Ano de publicação: 1999